Tirzepatide 5 mg held cardiometabolic gains after dose step-down in SURMOUNT-MAINTAIN analysis

At the European Society of Cardiology (ESC) 2026 meeting, researchers presented a post-hoc analysis of the Phase IIIb SURMOUNT-MAINTAIN trial showing that people taking tirzepatide kept improvements in blood pressure and other cardiometabolic markers after their dose was lowered from the maximum tolerated dose to 5 mg ^[1]. The analysis examined how those markers tracked with maintained weight reduction ^[1].

Tirzepatide is the molecule in Mounjaro and Zepbound. The dose studied here, 5 mg, is a step down from whatever dose each patient had reached and tolerated before the reduction ^[1]. That makes the analysis a look at maintenance and step-down rather than at starting treatment or pushing to a higher dose.

SURMOUNT-MAINTAIN is a Phase IIIb trial, and this report is a post-hoc analysis, meaning it looks back at data from a study that was designed for another purpose ^[1]. Post-hoc analyses can show patterns and associations, but they are not set up to prove that one thing caused another.

Several details have not been disclosed. It has not been reported how many people were included in the analysis, how long they had been taking the lower dose, how large the changes in blood pressure or other markers were, or whether the results reached statistical significance ^[1]. It also has not been reported whether the analysis compared people who stepped down to 5 mg against people who stayed on a higher dose, or how many people were unable to maintain their weight reduction on the lower dose.

The findings were described as supporting a step-down strategy once weight comes off ^[1]. The report does not identify which patients might do well on a lower maintenance dose, or how long a step-down should last.

Why it matters for patients

Many people taking tirzepatide for weight loss eventually ask a practical question: once the weight is off, do they have to stay on the highest dose they tolerated? This analysis suggests that for at least some patients, a lower maintenance dose of 5 mg was accompanied by sustained improvements in blood pressure and other cardiometabolic measures ^[1]. If that holds up, it could matter for side effects and for how much drug a person needs over the long term.

What this does not do is settle the question. Because the work is a post-hoc analysis, the maintained improvements cannot be attributed to the dose reduction itself on the basis of this report ^[1]. The report also does not say how the step-down was managed, whether anyone regained weight after lowering the dose, or whether the results differed by starting dose, by how much weight was lost, or by other health conditions.

It has not been reported whether a lower maintenance dose would change what patients pay, how insurers cover the drugs, or whether the findings would be reflected in prescribing information. Nothing in the report supports changing a dose without a prescriber's involvement; dose decisions remain a clinical judgment based on the individual patient.

What happens next

So far, the findings exist as a presentation at ESC 2026 ^[1]. It has not been disclosed whether the full SURMOUNT-MAINTAIN results or this analysis will be published in a peer-reviewed journal, or when. It also has not been reported whether the drugmakers or regulators have responded to the finding, or whether any step-down guidance for tirzepatide is under consideration. Until more detail is available, the size and durability of the effect reported at the meeting remain unknown.